Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of CVL006 combined with 9MW2821 in advanced solid tumors
CTR20261363Phase 2Active
- Sponsor
- Convalife Pharmaceutical
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CVL006, bulumtatug fuvedotin in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), sponsored by Convalife Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
CVL006bulumtatug fuvedotin
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20261363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261363.